Siu Steven W K, Law Martin, Liu Rico K Y, Wong K H, Soong Inda S, Kwok Annie O L, Ng K H, Lam P T, Leung T W
1Department of Clinical Oncology, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
Am J Hosp Palliat Care. 2014 May;31(3):281-6. doi: 10.1177/1049909113487022. Epub 2013 May 5.
REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results. This prospective study aims to determine whether methylphenidate is useful for relieving fatigue in Chinese patients with cancer. Chinese Version of Brief Fatigue Inventory (BFI-C) was administered on days 1, 8, and 29. Methylphenidate dose on day 1 was 5 mg daily then adjusted after day 8 according to response and side effects tolerance.
Only 48% of the 25 recruited patients were on methylphenidate by day 29. Overall, no significant improvement in fatigue level was observed after methylphenidate, though benefits were shown in subgroups with age ≤ 65 and higher baseline BFI-C values.
Methylphenidate may be useful for management of cancer-related fatigue in selected Chinese patients.
研究理由：关于哌甲酯治疗癌症相关疲劳的研究结果相互矛盾。这项前瞻性研究旨在确定哌甲酯对缓解中国癌症患者的疲劳是否有用。在第1、8和29天使用中文版简明疲劳量表（BFI-C）。第1天哌甲酯剂量为每日5毫克，然后在第8天后根据反应和副作用耐受性进行调整。
在招募的25名患者中，到第29天只有48%的患者服用哌甲酯。总体而言，服用哌甲酯后疲劳水平没有显著改善，尽管在年龄≤65岁和基线BFI-C值较高的亚组中显示出益处。
哌甲酯可能对特定中国患者的癌症相关疲劳管理有用。
